In this week's episode, we sat down with TechTarget News Director Jim O'Donnell to discuss the the recent wave of layoffs in the tech industry, focusing on Meta's strategic moves and the broader implications of AI transformation on employment, roles, and company culture. O'Donnell provides expert insights into how AI is reshaping the workforce and what the future might hold.

In this episode, we cover:

• Meta's layoffs and AI strategy
• Changing workforce dynamics and soft skills
• Future challenges for new entrants in tech

And more!

Find more tech news headlines by reading our Weekly Roundup.

Read more on techtarget.com/searchcio

A recent Red Access report revealed a staggering 5,000 vibe-coded apps in corporate environments, with 2,000 lacking proper security controls. This means sensitive data, including medical records, is floating around with no basic protections.

TechTarget.com's Kelsey Sung and Dark Reading's Rob Wright talk about the rapid evolution of shadow AI in light of this report. Employees aren't just using unauthorized tools, they’re creating apps that could be serving up sensitive information to hackers on a silver platter.

Dig into the Red Access report here: Red Access Request a Demo

Stay in the loop on other tech news this week: https://www.techtarget.com/searchcio/feature/Weekly-news-roundup-Googlebook-announced-WhatsApp-Incognito-Altman-under-fire-and-Foxconn-breach

Novo Nordisk teamed up with OpenAI, a partnership intended to shorten timelines and improve accuracy in drug development.

In this episode, Kelsey Sung interviews Cliff Saran of Computer Weekly about Novo Nordisk's groundbreaking partnership with OpenAI. They explore how AI is transforming drug development, reducing timelines, and addressing challenges in healthcare innovation. This collaboration also hints at a future where AI might reduce the need for animal testing, a controversial but promising step forward in ethical research.

Featuring: Cliff Saran, Computer Weekly

Read more: Novo Nordisk partners with OpenAI to AI-power drug development